Lion TCR’s T-Cell Therapy Gets Phase I/II Trial Approval

Singapore’s Health Sciences Authority has approved Lion TCR’s Phase I/II clinical study of immunotherapy for liver cancer.

AsianScientist (Sep. 5, 2018) – Lion TCR, a Singapore-based biotech company, has received approval from the Health Sciences Authority of Singapore (HSA) for its Phase I/II multicenter clinical study of its product candidate LioCyxTM. The drug is meant for the treatment of relapsed liver cancer after liver transplantation.

Liver cancer is the world’s third most deadly cancer with very limited treatment options and poor treatment outcome. Moreover, hepatitis B virus (HBV)-related liver cancer comprises at least 80 percent of all liver cancers diagnosed in Asia. There is currently no effective treatment available for patients whose liver cancer has relapsed post-liver transplantation.

To meet this urgent medical need, LioCyxTM is a precision T-cell receptor (TCR) immune cell therapy to target HBV-related liver cancer. The drug has been found to have a good safety profile, also demonstrating efficacy in investigator-sponsored trials carried out in Singapore and China.

“We are very delighted with the approval of Phase I/II clinical trial of our LioCyxTM, the first engineered TCR T-cell therapy for treatment of liver cancer in Singapore. HSA has been very efficient, transparent and professional in reviewing our application for the clinical trial of this immunotherapy,” said Dr. Victor Li Lietao, founder and CEO of Lion TCR.

The recruitment of patients for the Phase I/II clinical trial will begin at the National University Hospital, Singapore. Lion TCR is in the midst of including more medical centers in Singapore and China in the trial.


Source: Lion TCR; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist